AVIR News and Press, Atea Pharmaceuticals Inc. From 10/31/22

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report financial...

Atea Pharmaceuticals, Inc. ( NASDAQ: AVIR ), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosqu...

Dengue is the most prevalent mosquito-borne viral disease; endemic to 100 countries worldwide, with more than half the world’s populations at-risk AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development for treatment of dengue, showing potent ...

Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression Trial Expected to Initiate in Fourth Quarter 2022 Conference Call at...

BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Atea management will participate in the following investor events in September. Bemnifosbuvir Global Phase 3 ...

Image source: The Motley Fool. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q2 2022 Earnings Call Aug 08, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Call Transcri...

Atea Pharmaceuticals, Inc. (AVIR) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founde...

The following slide deck was published by Atea Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Atea Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

Atea Pharmaceuticals press release ( NASDAQ: AVIR ): Q2 GAAP EPS of -$0.38 beats by $0.14 . Cash and Cash Equivalents of $684.5 million at June 30, 2022 compared to $764.4 million at December 31, 2021 For further details see: Atea Pharmaceuticals GAAP EPS of ...

Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data Demonstrate Bemnifosbuvir Retained Antiviral Activity Against Omicron Subvariant In Vitr...